Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (5860)	1/9/1999 4:06:00 PM
From: scaram(o)uche	Respond to of 6136

And for a long time now (eom)

To: sam who wrote (5860)	1/9/1999 4:25:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Hey Sam...been wondering if you sold out. Ever sell those covered calls yet. I've still been holding out for something...don't know what. May sell 'em next week if it looks like Albright's comments are gonna cause a sell off. sf

To: sam who wrote (5860)	1/9/1999 6:49:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

Two biotech MSDW analysts follow AGPH: Douglas Lind, M.D. and Christopher Leonard. Altho' neither one would talk to me personally by phone, I do have a written report from them that indicates an excellent knowledge of HIV/AIDS, particularly the various available treatment regimens, including those in clinical trials, particularly Remune, which they interpret as "invoking dramatic immune responses against HIV...To sum it up, we continue to believe Viracept will live up to expectations and that Remune has good potential to become an important new treatment for HIV...we believe Agouron's long-term outlook extends beyond VIRACEPT into the fields of cancer and infectious diseases." They anticipate Remune FDA regulatory filing in 2H99.